Principal Investigator: Randall Brown; Christopher Nicholas Co-I; Bri Deyo Program Manager
Description: The long-term goal for this and future work is the dissemination of interventions effective in preventing opioid addiction and related complications, such as overdose, among victims of traumatic injury. The research specifically aims to engage the high-risk population of traumatic injury victims to develop an implementable set of opioid risk screening items.
Brown, R. T., Deyo, B., Nicholas, C., Baltes, A., Hetzel, S., Tilhou, A., Quanbeck, A., Glass, J., O’Rourke, A., & Agarwal, S. (2022). Screening in Trauma for Opioid Misuse Prevention (STOMP): Results from a prospective cohort of victims of traumatic injury. Drug and alcohol dependence, 232, 109286. https://doi.org/10.1016/j.drugalcdep.2022.109286
Brown, R., Deyo, B., Riley, C., Quanbeck, A., Glass, J. E., Turpin, R., Hetzel, S., Nicholas, C., Cruz, M., & Agarwal, S. (2017). Screening in Trauma for Opioid Misuse Prevention (STOMP): study protocol for the development of an opioid risk screening tool for victims of injury. Addiction science & clinical practice, 12(1), 28. https://doi.org/10.1186/s13722-017-0097-6
Funding Source: UW-Madison Department of Family Medicine and Community Health
Principal Investigator: Alyssa Tilhou
Description: The research aims to evaluate how people who use drugs (PWUD) modify drug use behavior in response to the use of fentanyl test strips (FTS). Utilizing interviews and surveys to gather information directly from PWUD, findings will yield insight into the safety of FTS as well as highlight behaviors perceived as feasible among PWUD to minimize the risk of harm. A secondary goal of this study is to provide knowledge about the penetration of fentanyl into the drug supply and provide information that can guide interventions to decrease the risk of overdose.
Principal Investigator: Charles Raison (School of Human Ecology); Randall Brown Site PI; Christopher Nicholas Co-I; Bri Deyo Program Manager
Description: The purpose of this study is to evaluate the potential efficacy of a single 25 mg oral dose of psilocybin for MDD compared to the active placebo in otherwise medically-healthy participants, assessed as the difference between groups in changes in depressive symptoms from Baseline to Day 8 post-dose.
Source: Multi-Disciplinary Association for Psychedelic Studies (MAPS)
Principal Investigator: Rick Doblin (MAPS); Randall Brown & Christopher Nicholas Co-Site PI; Bri Deyo Program Manager
Description: This multi-site double-blind, placebo-controlled randomized Phase 3 study assesses the efficacy and safety of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy versus psychotherapy with placebo in participants diagnosed with at least severe posttraumatic stress disorder (PTSD).
Mitchell, J.M., Bogenschutz, M., Lilienstein, A…Nicholas, C.R…Brown, R. et al. (2021). MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nat Med27, 1025–1033. https://doi.org/10.1038/s41591-021-01336-3
Nicholas, C. R., Wang, J. B., Coker, A., Mitchell, J. M., Klaire, S. S., Yazar-Klosinski, B., Emerson, A., Brown, R. T., & Doblin, R. (2022). The effects of MDMA-assisted therapy on alcohol and substance use in a phase 3 trial for treatment of severe PTSD. Drug and alcohol dependence, 233, 109356. https://doi.org/10.1016/j.drugalcdep.2022.109356